Bibliography
- Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006;58:58-86
- North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-67
- Ferrari D, Pizzirani C, Adinolfi E, The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006;176:3877-83
- Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002;20:S1-13
- Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989;243:1160-5
- Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
- Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem 1995;270:27758-65
- Thornberry NA, Bull HG, Calaycay JR, A novel heterodimeric cysteine protease is required for interleukin-1beta processing in monocytes. Nature 1992;356:768-74
- Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006;126:659-62
- MacKenzie A, Wilson HL, Kiss-Toth E, Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001;15:825-35
- Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007;27:98-114
- Parvathenani LK, Tertyshnikova S, Greco CR, P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 2003;278:13309-17
- Di Virgilio F, Chiozzi P, Ferrari D, Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001;97:587-600
- Pelegrin P, Surprenant A. The P2X7 receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal 2009;5:129-37
- Beigi RD, Kertesy SB, Aquilina G, Dubyak GR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol 2003;140:507-19
- Buell GN, Talabot F, Gos A, Gene structure and chromosomal localization of the human P2X7 receptor. Receptors Channels 1998;5:347-54
- Fuller SJ, Stokes L, Skarratt KK, Genetics of the P2X7 receptor and human disease. Purinergic Signal 2009;5:257-62
- Wiley JS, Dao-Ung LP, Li C, An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 2003;278:17108-13
- Barden N, Harvey M, Gagne B, Analysis of single nucleotide polymorphisms in genes in the chromosome 12q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2006;141B:374-82
- Lucae S, Salyakina D, Barden N, P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006;15:2438-45
- Adinolfi E, Melchiorri L, Falzoni S, P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002;99:706-8
- Adinolfi E, Callegari MG, Cirillo M, Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 2009;284:10120-8
- Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006;176:3044-52
- Adinolfi E, Callegari MG, Ferrari D, Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 2005;16:3260-72
- Martel-Gallegos G, Rosales-Saavedra MT, Reyes JP, Human neutrophils do not express purinergic P2X7 receptors. Purinergic Signal 2010;6:297-306
- Christenson K, Bjorkman L, Tangemo C, Bylund J. Serum amyloid inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. J Leukoc Biol 2008;83:139-48
- North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 2000;40:563-80
- Gudmundsson GH, Agerberth B, Odeberg J, The human gene fall39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238:325-32
- Oren Z, Lerman JC, Gudmundsson GH, Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999;341:501-13
- Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1beta processing and release. J Immunol 2004;172:4987-94
- Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006;1758:1408-25
- Turner CM, Vonend O, Chan C, The pattern of distribution of selected ATP-sensitive p2 receptor subtypes in normal rat kidney: an immunohistological study. Cells Tissues Organs 2003;175:105-17
- Harada H, Chan CM, Loesch A, Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int 2000;57:949-58
- Vonend O, Turner CM, Chan CM, Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 2004;66:157-66
- Goncalves RG, Gabrich L, Rosario A Jr, The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 2006;70:1599-606
- Turner CM, Tam FW, Lai PC, Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 2007;22:386-95
- Taylor SR, Turner CM, Elliott JI, P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009;20:1275-81
- Raby BA, Silverman EK, Lazarus R, Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Hum Mol Genet 2003;12:1973-9
- Mizuno K, Okamoto H, Horio T. Heightened ability of monocytes from sarcoidosis patients to form multi-nucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells. Clin Exp Immunol 2001;126:151-6
- Wareham K, Vial C, Wykes RC, Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. Br J Pharmacol 2009;157:1215-24
- Fernando SL, Saunders BM, Sluyter R, A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 2007;175:360-6
- Nino-Moreno P, Portales-Perez D, Hernandez-Castro B, P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis. Clin Exp Immunol 2007;148:469-77
- Waxman AB, Einarsson O, Seres T, Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 1998;101:1970-82
- Kolliputi N, Shaik RS, Waxman AB. The inflammasome mediates hyperoxia-induced alveolar cell permeability. J Immunol 2010;184:5819-26
- Lucattelli M, Cicko S, Muller T, P2X7 receptor signalling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am J Respir Cell Mol Biol 2011;44:423-9
- Muller T, Paula Vieira R, Grimm M, A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 2011;44:456-64
- Riteau N, Gasse P, Fauconnier L, Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010;182:774-83
- Denlinger LC, Shi L, Guadarrama A, Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med 2009;179:265-70
- Rich PB, Douillet CD, Mahler SA, Adenosine triphosphate is released during injurious mechanical ventilation and contributes to lung edema. J Trauma 2003;55:290-2977
- Ryan LM, Rachow JW, McCarty DJ. Synovial fluid ATP: a potential substrate for the production of inorganic pyrophosphate. J Rheumatol 1991;18:716-20
- Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-7
- Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440
- Caporali F, Capecchi PL, Gamberucci A, Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med 2008;86:937-49
- Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1beta production and P2x7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 2008;31:84-90
- Wang D, Bromme D. Drug delivery strategies for cathepsin inhibitors in joint diseases. Expert Opin Drug Deliv 2005;2:1015-28
- Nakagawa TY, Brissette WH, Lira PD, Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin s null mice. Immunity 1999;10:207-17
- Lopez-Castejon G, Theaker J, Pelegrin P, P2X7 receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol 2010;185:2611-19
- Dell'Antonio G, Quattrini A, Cin ED, Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 2002;46:3378-85
- Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-75
- Kokubun M, Imafuku Y, Okada M, Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta 2005;360:97-102
- Bianco F, Fumagalli M, Pravettoni E, Pathophysiological roles of extracellular nucleotides in glial cells: differential expression of purinergic receptors in resting and activated microglia. Brain Res Brain Res Rev 2005;48:144-56
- Takenouchi T, Nakai M, Iwamaru Y, The activation of P2X7 receptor impairs lysosomal functions and stimulates the release of autophagolysosomes in microglial cells. J Immunol 2009;182:2051-62
- Wang LY, Cai WQ, Chen PH, Downregulation of P2X7 receptor expression in rat oligodendrocyte precursor cells after hypoxia ischemia. Glia 2009;57:307-19
- Domercq M, Perez-Samartin A, Aparicio D, P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 2010;58:730-40
- Chessell IP, Hatcher JP, Bountra C, Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005;114:386-96
- McGaraughty S, Chu KL, Namovic MT, P2X7-related modulation of pathological nociception in rats. Neuroscience 2007;146:1817-28
- Angus DC, Linde-Zwirble WT, Lidicker J, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10
- Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001;276:3820-6
- Novogrodsky A, Vanichkin A, Patya M, Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 1994;264:1319-22
- Li P, Allen H, Banerjee S, Mice deficient in IL-1beta-converting enzyme are defective in production of mature IL-1beta and resistant to endotoxic shock. Cell 1995;80:401-11
- Chiao CW, Tostes RC, Webb RC. P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1beta release. J Pharmacol Exp Ther 2008;326:864-70
- Opal SM, Fisher CJ Jr, Dhainaut JF, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med 1997;25:1115-24
- Hotchkiss RS, Swanson PE, Knudson CM, Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999;162:4148-56
- Hotchkiss RS, Tinsley KW, Swanson PE, Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001;166:6952-63
- Chung CS, Song GY, Lomas J, Inhibition of Fas/Fas ligand signaling improves septic survival: Differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 2003;74:344-51
- Aswad F, Dennert G. P2X7 receptor expression levels determine lethal effects of a purine based danger signal in T lymphocytes. Cell Immunol 2006;243:58-65
- Brealey D, Brand M, Hargreaves I, Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360:219-23
- Adinolfi E, Callegari MG, Cirillo M, Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem 2009;284:10120-8
- Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301-8
- Jo SK, Cha DR, Cho WY, Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells. Nephron 2002;91:406-15
- Yang B, Johnson TS, Thomas GL, Apoptosis and caspase-3 in experimental anti-glomerular basement membrane nephritis. J Am Soc Nephrol 2001;12:485-95
- Sugiyama H, Kashihara N, Makino H, Apoptosis in glomerular sclerosis. Kidney Int 1996;49:103-11
- Lovett DH, Sterzel RB. Cell culture approaches to the analysis of glomerular inflammation. Kidney Int 1986;30:246-54
- Parikh CR, Jani A, Melnikov VY, Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004;43:405-14
- Melnikov VY, Ecder T, Fantuzzi G, Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 2001;107:1145-52
- Liu HF, Liang D, Wang LM, Effects of specific interleukin-1beta-converting enzyme inhibitor on ischemic acute renal failure in murine models. Acta Pharmacol Sin 2005;26:1345-51
- Furuichi K, Wada T, Iwata Y, Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit Care Med 2006;34:2447-55
- Wang W, Faubel S, Ljubanovic D, Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol 2005;288:F997-F1004
- Schmidt C, Hocherl K, Schweda F, Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol 2007;18:1072-83
- Tam FW, Smith J, Morel D, Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 1999;14:1658-66
- Taylor SR, Gonzalez-Begne M, Dewhurst S, Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J Immunol 2008;180:300-8
- Gauer S, Sichler O, Obermuller N, IL-18 is expressed in the intercalated cell of human kidney. Kidney Int 2007;72:1081-7
- Lemaire I, Falzoni S, Leduc N, Involvement of the purinergic P2X7 receptor in the formation of multinucleated giant cells. J Immunol 2006;177:7257-65
- Dell'Antonio G, Quattrini A, Dal Cin E, Antinociceptive effect of a new P2Z/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 2002;327:87-90
- AstraZeneca. An open, randomised, 2-way crossover study to establish the absolute bioavailability of AZD9056 in tablet formulation (200 mg) compared with an intravenous formulation (25 mg), in healthy volunteers (study code: D1520c05285) 2003. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10629864 [Last accessed 8 April 2011]
- AstraZeneca. A Phase I, double-blind, placebo-controlled, randomised, group vcomparative study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9056 in healthy volunteers (study code: D1520c05216). 2004. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10631407 [Last accessed 8 April 2011]
- AstraZeneca. An open, non-randomised, crossover study to investigate the effect of AZD9056 (50 mg oral dose for 5 days) on cytochrome P450 3A using the probe drug midazolam (7.5 mg oral and 1 mg intravenous dose) (study code d1520c00002) 2005. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10775659 [Last accessed 8 April 2011]
- AstraZeneca. A randomised, double-blind placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of AZD9056 administered for 28 days in patients with osteoarthritis of the knee (study code: D1522c00001). 2005. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10745200 [Last accessed 8 April 2011]
- McInnes IB, Snell NJ, Perrett JH, Results of a Phase II clinical trial of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (create study). 2007. Available from: http://acr.confex.com/acr/2007/webprogram/Paper8110.html [Last accessed 8 April 2011]
- AstraZeneca. A randomised, double-blind, placebo-controlled, parallel group, ascending dose study to assess the activity, safety and tolerability of 2 doses of AZD9056 for 4 weeks in patients with active rheumatoid arthritis receiving methotrexate and/or sulphasalazine (study code: D1520c05287). 2006. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10645408 [Last accessed 8 April 2011]
- Pfizer. A Phase 1, double blind study of the safety and pharmacokinetics of multiple doses of CE 224,535 in subjects with rheumatoid arthritis receiving methotrexate. Clinicaltrials.Gov NCT00446784. Available from: http://clinicaltrials.gov/ct2/show?term=CE-+224%2C+535&rank=1
- Pfizer. A 2 week, randomized, double blind, placebo and positive controlled, parallel group, multicenter study of CE-224,535 in subjects with osteoarthritic pain of the knee. Clinicaltrials.Gov identifier: NCT00418782. Available from: http://clinicaltrials.gov/ct2/show?term=CE-+224%2C+535&rank=5
- AstraZeneca. A Randomised, Double-blind, Placebo-controlled, Parallel-group,Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD (study code: D1521c00002) 2007. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10775742 [Last accessed 8 April 2011]
- Pfizer. A Phase 2a, randomized, double-blind, placebo-controlled, parallel-group study of CE-224,535, an antagonist of the P2x7 receptor, in the treatment of the signs and symptoms of rheumatoid arthritis in subjects who are inadequately controlled on methotrexate. Clinicaltrials.Gov NCT00628095. Available from: http://clinicaltrials.gov/ct2/show?term=CE224%2C535&rank=2
- Pfizer. A Phase 1, randomized, 4-period, 4-sequence cross-over study of the pharmacokinetics of 3 durations of release of a controlled release formulation and a single dose of an immediate release oral suspension of CE-224,535 in normal healthy volunteers. Clinicaltrials.Gov NCT00782600. Available from: http://clinicaltrials.gov/ct2/show?term=CE-+224%2C+535&rank=4
- AstraZeneca. A randomised, double-blind (with open comparator etanercept limb), placebo-controlled, Phase IIb, multicentre study to evaluate the efficacy of 4 doses of AZD9056 administered for 6 months on the signs and symptoms of rheumatoid arthritis in patients with active disease receiving background methotrexate or sulphasalazine. Clinicaltrials.Gov NCT00520572. Available from: http://clinicaltrials.gov/ct2/show/NCT00520572?term=AZD9056&rank=5
- AstraZeneca. A Phase I, single centre, open-label study to assess the pharmacokinetics of both AZD9056 (steady state) and simvastatin (single dose) when co-administered in healthy volunteers. Clinicaltrials.Gov NCT00736606. Available from: http://clinicaltrials.gov/ct2/show/NCT00736606?term=AZD9056&rank=4
- AstraZeneca. A randomised, double-blind, placebo-controlled, 2-period cross-over study in healthy male volunteers, to investigate retinal function following a single 800mg oral dose of AZD9056. Clinicaltrials.Gov: NCT00700986. Available from: http://clinicaltrials.gov/ct2/show/NCT00700986?term=AZD9056&rank=3
- AstraZeneca. Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active crohn´s disease-a randomized, pilot, double-blind, four week, parallel-group, multicentre, phase II study (AZD9056; astra zeneca) (study code d8830c00002) 2008. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10746961 [Last accessed 8 April 2011]
- Ad hoc: Evotec Announces the Successful Completion of the First Phase I Study with EVT 401. Hamburg, Germany, 2008. Available from: http://www.evotec.com/article/en/Adhoc-Releases/Ad-hoc-Evotec-Announces-the-Successful-Completion-of-the-First-Phase-I-Study-with-EVT-401/347?selected_category_id= [Last accessed 8 April 2011]
- Pfizer, An open-label two-part randomized, crossover study of the pharmacokinetics of CE-224,535 administered as controlled and immediate release formulations in healthy volunteers. Clinicaltrials.Gov NCT00838058. Available from: http://clinicaltrials.gov/ct2/show?term=CE-+224%2C+535&rank=3
- AstraZeneca. An open-label, randomized, 2 cohort, 2 period crossover study to assess the relative bioavailability of the Phase III to the Phase IIb formulation of AZD9056 in healthy male and female subjects. Clinicaltrials.Gov NCT00908934. Available from: http://clinicaltrials.gov/ct2/show?term=AZD9056&rank=1
- AstraZeneca. An Open-label, Randomized, 2-cohort, 2-period Crossover Study to Assessthe Relative Bioavailability of the Phase III to the Phase IIb Formulation of AZD9056 in Healthy Male and Female Subjects (study code d1520c00004) 2009. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10776007 [Last accessed 8 April 2011]
- AstraZeneca. A randomised, double-blind (with open comparator etanercept limb), placebo- controlled, Phase IIb, multicentre study to evaluate the efficacy of 4 doses of AZD9056 administered for 6 months on the signs and symptoms of rheumatoid arthritis in patients with active disease receiving background methotrexate or sulphasalazine (study code d1520c00001). 2009. Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/10775953 [Last accessed 8 April 2011]
- GlaxoSmithKline. A first-time-in-human randomised, single blind placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics, of single escalating doses of GSK1482160, in male and female healthy subjects, and to make a preliminary assessment of the effect of food. Clinicaltrials.Gov NCT00849134. Available from: http://clinicaltrials.gov/ct2/show/NCT00849134?term=GSK1482160&rank=1
- Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 2004;286:C1100-8
- Eder C. Mechanisms of interleukin-1beta release. Immunobiology 2009;214:543-53
- Brough D, Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci 2007;120:772-81
- Pelegrin P, Surprenant A. The P2X7 receptor-pannexin connection to dye uptake and IL-1beta release. Purinergic Signal 2009;5:129-37